减肥药“断腕”、核心药物承压辉瑞欲“买买买”加码心脏代谢短板

动脉网
Yesterday

辉瑞在2025年第一季度财报中披露,由于口服减肥药Danuglipron研发受挫,公司将通过收购或合作加速布局心脏代谢领域,以弥补产品线空缺。尽管Q1营收未达预期,但调整后每股收益超预期,公司维持全年盈利指引上限。新冠产品表现不一,Paxlovid收入低于预期,而Comirnaty疫苗超出预期。核心药物如Eliquis销售额下滑。为应对业绩波动,辉瑞升级成本管控计划,预计到2027年底累计节省57...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10